v. Absolute neutrophil count < 1000/mm 3 . 
vi. Creatinine > 2.0 mg/dl. 
vii. Total bilirubin > 2.0 mg/dl. 
viii. SGOT and SGPT > 4 times upper limit of normal reference value. 
b) Current or previous AIDS (Acquired Immunodeficiency Syndrome)-defining 
opportunistic infection (revised 1993 CDC criteria, ref. 1), Kaposi's Sarcoma, 
lymphoma, cervical or other carcinoma, or hairy leukoplakia. 
c) Pregnant or nursing women. 
d) An acute infectious illness within one month of initiation of treatment. 
e) Any other serious chronic illness including, but not limited to: diabetes, chronic 
active hepatitis, sarcoidosis, active autoimmune disease (such as rheumatoid 
arthritis, systemic lupus erythematosus, Reiter's Syndrome, inflammatory bowel 
disease, thyroiditis, etc.), coronary artery disease, cardiomyopathy, chronic 
obstructive pulmonary disease, dementia. 
f ) Patients receiving systemic glucocorticosteroids. 
g) Allergy to penicillin, streptomycin or amphotericin B. 
h ) Active alcohol abuse or drug abuse or psychiatric impairment or occupational or 
personal circumstances that in the opinion of the investigators would prevent 
compliance with the protocol. 
i ) Patients who have undergone alternative non-FDA approved treatment within four 
weeks of initiation of the protocol. 
5. GENE TRANSFER PROTOCOL 
A. Enrollment: Subjects who meet the eligibility requirements will have the study 
explained in detail to them by Dr. Eric Poeschla or Dr. David Looney (designated 
at points in the protocol as investigating physicians). Subjects will then be asked to 
give witnessed, informed consent in writing (see Sections 10 and 11 below). 
[390] 
Recombinant DNA Research, Volume 18 
